AU2021333748A1 - Viral inhibitors - Google Patents

Viral inhibitors Download PDF

Info

Publication number
AU2021333748A1
AU2021333748A1 AU2021333748A AU2021333748A AU2021333748A1 AU 2021333748 A1 AU2021333748 A1 AU 2021333748A1 AU 2021333748 A AU2021333748 A AU 2021333748A AU 2021333748 A AU2021333748 A AU 2021333748A AU 2021333748 A1 AU2021333748 A1 AU 2021333748A1
Authority
AU
Australia
Prior art keywords
mole
substituted
group
amphiphilic
unsubstituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2021333748A
Other languages
English (en)
Inventor
Emilia BARRETO DURAN
Aleksandra MILEWSKA
Krzysztof Pyrc
Andreas Schatzlein
Ijeoma Uchegbu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nanomerics Ltd
Original Assignee
Nanomerics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2013221.3A external-priority patent/GB202013221D0/en
Priority claimed from GBGB2019097.1A external-priority patent/GB202019097D0/en
Priority claimed from GBGB2105404.4A external-priority patent/GB202105404D0/en
Application filed by Nanomerics Ltd filed Critical Nanomerics Ltd
Publication of AU2021333748A1 publication Critical patent/AU2021333748A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/722—Chitin, chitosan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2021333748A 2020-08-24 2021-08-24 Viral inhibitors Abandoned AU2021333748A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB2013221.3 2020-08-24
GBGB2013221.3A GB202013221D0 (en) 2020-08-24 2020-08-24 Viral inhibitors
GB2019097.1 2020-12-03
GBGB2019097.1A GB202019097D0 (en) 2020-12-03 2020-12-03 Viral inhibitors
GBGB2105404.4A GB202105404D0 (en) 2021-04-15 2021-04-15 Viral inhibitors
GB2105404.4 2021-04-15
PCT/GB2021/052199 WO2022043678A1 (en) 2020-08-24 2021-08-24 Viral inhibitors

Publications (1)

Publication Number Publication Date
AU2021333748A1 true AU2021333748A1 (en) 2023-03-23

Family

ID=77655566

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021333748A Abandoned AU2021333748A1 (en) 2020-08-24 2021-08-24 Viral inhibitors

Country Status (8)

Country Link
US (1) US20230330132A1 (https=)
EP (1) EP4199937A1 (https=)
JP (1) JP2023538449A (https=)
CN (1) CN116367843A (https=)
AU (1) AU2021333748A1 (https=)
CA (1) CA3192515A1 (https=)
MX (1) MX2023002109A (https=)
WO (1) WO2022043678A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3194032A1 (en) * 2020-09-04 2022-03-10 The University Of Chicago Materials and methods of treating viral infection with amphiphilic block copolymers

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0221941D0 (en) * 2002-09-20 2002-10-30 Univ Strathclyde Polysoaps
CN100577179C (zh) * 2003-05-08 2010-01-06 天津帝士力投资控股集团有限公司 甲壳素和壳聚糖及其衍生物在制备抗病毒剂中的应用
GB0320638D0 (en) * 2003-09-03 2003-10-01 Novartis Ag Organic compounds
US7968122B2 (en) * 2003-12-10 2011-06-28 Adventrx Pharmaceuticals, Inc. Anti-viral pharmaceutical compositions
GB0615834D0 (en) 2006-08-09 2006-09-20 Univ Glasgow Polymeric micellar clusters and their uses in formulating drugs
JP6028968B2 (ja) * 2012-02-24 2016-11-24 学校法人順天堂 抗インフルエンザウイルス剤
PL225045B1 (pl) * 2012-05-18 2017-02-28 Univ Jagiellonski Zastosowanie polimeru chitozanowego do wytwarzania leków do leczenia i profilaktyki infekcji wywołanych przez koronawirusy
GB201319437D0 (en) * 2013-11-04 2013-12-18 Nanomerics Ltd Delivery of drugs
WO2020039463A1 (en) * 2018-08-23 2020-02-27 Haskoli Islands Chitosan derivatives and methods for preparing the same

Also Published As

Publication number Publication date
CN116367843A (zh) 2023-06-30
CA3192515A1 (en) 2022-03-03
MX2023002109A (es) 2023-07-13
WO2022043678A1 (en) 2022-03-03
EP4199937A1 (en) 2023-06-28
JP2023538449A (ja) 2023-09-07
US20230330132A1 (en) 2023-10-19

Similar Documents

Publication Publication Date Title
KR102140989B1 (ko) 개선된 점막 수송을 나타내는 제약 나노입자
JP7510181B2 (ja) 殺ウイルス性ナノ粒子及びインフルエンザウイルスに対するその使用
CA2859046A1 (en) Nanoparticles with enhanced mucosal penetration or decreased inflammation
US12239629B2 (en) Methods for the prophylaxis and treatment of COVID and COVID-19
EP4110334A1 (en) Methods and compositions using synthetic nanocarriers comprising immunosuppressant
AU2021333748A1 (en) Viral inhibitors
WO2022026622A2 (en) Treatment of viral diseases
WO2023150375A2 (en) Methods and compositions for treating covid infections
WO2021236626A1 (en) Mucoretentive antiviral technologies
US20230256049A1 (en) Materials and methods for the prevention and treatment of viral respiratory diseases
Jones et al. Small molecule antivirals to nanoparticles: The need of the hour to combat pandemics
WO2025240286A1 (en) Neuron targeted 2-deoxyglucose dendrimer for imaging and treatment of neurological diseases
Alshammari et al. Rifampicin-Loaded Nanoparticles for Targeted Tuberculosis Therapy: Enhancing Delivery and Efficacy
HK40076071A (en) Pharmaceutical nanoparticles showing improved mucosal transport
Alcantara Development of mucoadhesive polymeric nanoparticles for intranasal delivery of Favipiravir in treating SARS-CoV-2 infection
CN121401419A (zh) 针对vdac1靶点的物质在制备产品中的应用以及防治由rsv引起的疾病的药物

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period